Novo’s Alzheimer’s Bet on Ozempic Misses | Open Interest 11/24/2025

Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." Big Tech’s cautious comeback — but can it last amid a debt-fueled spending spree?And Novo Nordisk stumbles as its Alzheimer’s drug trial fails — sending shares toward their worst year ever. Plus, hedge fund titan Ray Dalio says Wall Street’s hottest investing trend may not stand the test of time. Meanwhile, Americans are drinking less, but chilling more. Bloomberg Open Interest will take you inside the rise of anti-anxiety drinks — and the brand that’s turning calm into cash. (Source: Bloomberg)